Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-02 |
2024-03 |
0.75 |
0.59 |
-0.16 |
-21.33% |
2024-02-22 |
2023-12 |
1.01 |
1.15 |
0.14 |
13.86% |
2023-11-02 |
2023-09 |
0.92 |
1.03 |
0.11 |
11.96% |
2023-08-03 |
2023-06 |
0.75 |
0.81 |
0.06 |
8.00% |
2023-05-04 |
2023-03 |
0.75 |
0.52 |
-0.23 |
-30.67% |
2023-02-23 |
2022-12 |
0.92 |
1.02 |
0.1 |
10.87% |
Date |
Firm |
Action |
From |
To |
2023-09-19 |
Jefferies |
Upgrade |
Hold |
Buy |
2023-06-15 |
TD Cowen |
Downgrade |
Outperform |
Market Perform |
2023-05-21 |
Jefferies |
Upgrade |
Buy |
Buy |
2023-05-04 |
RBC Capital |
Upgrade |
|
Sector Perform |
2022-09-08 |
Piper Sandler |
Upgrade |
|
Neutral |
2022-08-31 |
RBC Capital |
Upgrade |
|
Sector Perform |
Date |
Name |
Relation |
Quantity |
Description |
2024-05-16 |
GARCIA CHRISTIAN A |
Director |
35.36K |
Stock Award(Grant) |
2024-05-16 |
ICAHN BRETT |
Director |
143.86K |
Stock Award(Grant) |
2024-05-16 |
KAVANAGH SARAH BALDWIN |
Director |
182.01K |
Stock Award(Grant) |
2024-05-16 |
LEE FRANK DON |
Director |
35.36K |
Stock Award(Grant) |
2024-05-16 |
MILLER STEVEN D |
Director |
184.88K |
Stock Award(Grant) |
2024-05-20 |
MULLIGAN RICHARD CHARLES PH.D |
Director |
65.91K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Icahn Carl C |
34.72M |
277.77M |
9.62% |
2023-06-29 |
Paulson & Company, Inc. |
26.44M |
211.51M |
7.32% |
2023-06-29 |
Goldentree Asset Management LP |
20.06M |
160.45M |
5.56% |
2023-06-29 |
Franklin Resources, Inc. |
16.57M |
132.60M |
4.59% |
2023-09-29 |
National Bank of Canada/FI |
15.66M |
128.74M |
4.34% |
2023-06-29 |
Bank of Montreal/Can/ |
15.06M |
120.46M |
4.17% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Franklin Custodian Funds-Income Fund |
15.00M |
120.00M |
4.16% |
2023-07-30 |
Vanguard International Stock Index-Total Intl Stock Indx |
4.24M |
41.20M |
1.18% |
2023-06-29 |
Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund |
2.52M |
20.15M |
0.70% |
2023-07-30 |
DFA Investment Dimensions-Canadian Small Company Series |
1.55M |
15.07M |
0.43% |
2023-07-30 |
Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index |
1.23M |
11.98M |
0.34% |
2023-08-30 |
Invesco ETF Tr-Invesco Dynamic Pharmaceuticals ETF |
1.20M |
10.01M |
0.33% |
Dividend |
Date |
1 |
2010-11-10 |
0.095 |
2010-08-30 |
0.095 |
2010-05-31 |
0.095 |
2010-05-28 |
0.09 |
2010-03-04 |
0.09 |
2009-11-30 |
Split |
Date |
2 : 1 |
2000-10-16 |
2 : 1 |
2000-01-20 |
1 : 2 |
2000-01-10 |
3 : 1 |
1996-01-17 |